Advertisement
Screener

COCRYSTAL PHARMA, INC. (COCP) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.2 / 5 stars · 14/60 Roast Me

COCRYSTAL PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

COCRYSTAL PHARMA, INC. (COCP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 1-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-13

  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
  • COCRYSTAL PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-08-13
2026-03-310.00%
10-Q · filed 2026-05-15
2026-01-310.00%
10-Q · filed 2026-08-13
2025-03-310.00%
10-Q · filed 2026-05-15
2023-12-310.00%
10-K · filed 2025-03-31
2023-09-300.00%
10-Q · filed 2023-11-13
2023-06-300.00%
10-Q · filed 2023-08-14
2023-03-310.00%
10-Q · filed 2023-05-15
2022-12-310.00%
10-K · filed 2024-03-28
2022-09-300.00%
10-Q · filed 2023-11-13
2022-06-300.00%
10-Q · filed 2023-08-14
2022-03-310.00%
10-Q · filed 2023-05-15
2021-12-310.00%
10-K · filed 2023-03-29
2021-09-300.00%
10-Q · filed 2022-11-14
2021-06-300.00%
10-Q · filed 2022-08-15
2021-03-310.00%
10-Q · filed 2022-05-11
2020-12-310.00%
10-K · filed 2022-03-23
2020-09-300.00%
10-Q · filed 2021-11-15
2019-09-300.00%
10-Q · filed 2020-11-13
2018-12-310.00%
10-K · filed 2020-03-27
2016-12-310.00%
10-K · filed 2017-03-31
2015-12-310.00%
10-K · filed 2018-03-21
2013-09-300.00%
10-Q · filed 2013-11-18
2013-06-300.00%
10-Q · filed 2013-08-15
2013-03-310.00%
10-Q · filed 2013-05-10
2012-09-300.00%
10-Q · filed 2012-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
NextCure, Inc. (NXTC)United States$0.024B-0.15
Rocket One Inc. (RKTO)United States$0.019B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62